Prelude Therapeutics Q4 2024 Earnings Report $0.68 -0.03 (-4.67%) As of 11:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Prelude Therapeutics EPS ResultsActual EPS-$0.38Consensus EPS -$0.49Beat/MissBeat by +$0.11One Year Ago EPSN/APrelude Therapeutics Revenue ResultsActual Revenue$4.00 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APrelude Therapeutics Announcement DetailsQuarterQ4 2024Date3/10/2025TimeBefore Market OpensConference Call ResourcesPRLD Earnings History Remove Ads Prelude Therapeutics Earnings HeadlinesPrelude Therapeutics Founder Acquires 28% More StockMarch 29, 2025 | finance.yahoo.comPrelude Therapeutics CEO buys $467K in common stockMarch 28, 2025 | markets.businessinsider.comElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the timing perfect. Silver surged 23% in 2024. If Musk moves into silver, prices could explode—and those waiting on the sidelines will be left scrambling.April 4, 2025 | Priority Gold (Ad)Prelude Therapeutics stock surges on insider buyingMarch 27, 2025 | investing.comPrelude Therapeutics Reports 2024 Financial Results and Clinical Pipeline AdvancementsMarch 14, 2025 | msn.comAnalysts Are Bullish on Top Healthcare Stocks: Prelude Therapeutics (PRLD), Corbus Pharmaceuticals (CRBP)March 12, 2025 | markets.businessinsider.comSee More Prelude Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Prelude Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prelude Therapeutics and other key companies, straight to your email. Email Address About Prelude TherapeuticsPrelude Therapeutics (NASDAQ:PRLD), a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.View Prelude Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Lamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go Higher Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.